NAD+ Biology and Multi-Component Nutraceutical Support for Cellular Energy, Healthy Ageing, Cognition, Cardiovascular Wellness, Stress Adaptation and Fatigue A Critical Review with Reference to the Biotex NAD+ Formulation
Keywords:
NAD+, nicotinamide, coenzyme Q10, ubiquinol, Withania somnifera, Terminalia arjuna, adenosine 5'‑monophosphate, riboflavin, mitochondrial bioenergetics, atigue, cognition, stress adaptation, cardiovascular wellness; healthy ageingAbstract
Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and signalling substrate that links nutrient oxidation, mitochondrial electron transfer, DNA-damage responses, sirtuin activity and cellular stress adaptation. Interest in NAD+-supportive nutraceuticals has increased in parallel with human trials of nicotinamide riboside and nicotinamide mononucleotide and with preclinical work connecting NAD homeostasis to mitochondrial function and ageing. This critical review evaluates the biological and clinical evidence relevant to a multi-component nutraceutical, Biotex NAD+, containing Terminalia arjuna extract (150 mg), coenzyme Q10/ubiquinol-related material (100 mg), Withania somnifera extract (100 mg), adenosine 5'-monophosphate (50 mg), nicotinamide (14 mg) and riboflavin (2 mg) per capsule. Only peer-reviewed primary research reports were used as numbered evidentiary citations; review articles, systematic reviews, meta-analyses, editorials, protocols and preprints were excluded from the evidence set. Human randomised or controlled studies were prioritised, with mechanistic animal or cellular studies used when clinical data were unavailable. The strongest ingredient-level human support concerns CoQ10/ubiquinol for mitochondrial and fatigue-related outcomes, Withania somnifera for stress adaptation and selected cognitive outcomes, and T. arjuna for cardiovascular functional endpoints. Human NAD-precursor trials confirm that NAD metabolism is modifiable, but recent direct comparison shows sustained circulatory NAD+ elevation with nicotinamide riboside and nicotinamide mononucleotide rather than nicotinamide; therefore, the 14-mg nicotinamide content of the formulation should not be interpreted as proof that the finished product raises systemic NAD+. Evidence for healthy ageing is strongest at the mechanistic and preclinical levels, while human lifespan extension, cellular 'rejuvenation', direct ATP elevation and product-specific cognitive or cardiovascular efficacy remain unproven. Overall, the formulation has a coherent multi-pathway rationale for supporting energy metabolism, fatigue resistance, stress adaptation, cognitive wellness and cardiovascular function, but formulation-specific randomised trials are required to establish magnitude, reproducibility and dose relevance of these effects.
Published
Issue
Section

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

